Anyone hear anything...... recently about the prion inactivation research? Seems to me like they have been pretty quiet on this front. To be honest, I was kind of hoping that news on this front would have been part of my 1-2 punch theory. Perhaps we will get a 1-2-3 punch...
===
News from CNW Group
TSO3 to deliver presentation on prion sterilization research toexperts at meeting hosted by France's Health Products Safety Agency(AFSSAPS)
08:00 EST Monday, January 12, 2009
Stock symbol: TSX: TOS
Outstanding shares: 47,863,402
The Company will outline the latest data based on studies carried out by
the Health Protection Agency of the United Kingdom and sponsored by the
Department of Health on the effectiveness of its Ozone sterilization
technology to eliminate prion infection
QUEBEC, Jan. 12/CNW Telbec/ - Mr. R.M. (Ric) Rumble, President and Chief ExecutiveOfficer of TSO3 Inc. ("TSO3") (TSX: TOS), is pleased to announce thatthe Company will be presenting data to France's experts on prioninactivation methods for reusable medical devices. The Company willdisclose results of ongoing research pertaining to the use of itsproprietary ozone sterilization technology as a method for prioninactivation. This research project, sponsored by the Department ofHealth of theUnited Kingdom andcontracted out to the Health Protection Agency, uses the TSO3STERIZONE(R) 125L Ozone Sterilization Process to determine theeffectiveness of the technology in eliminating prion infection onmedical instruments.
The new data supports previous statements made in January 2008that the STERIZONE(R) 125L Ozone Sterilization Process shows promise asa technology which could be used to reduce the risk of prioncontamination. Additional confirmation studies are still in progressand the Company expects results from these studies in the comingmonths. The meeting, hosted by the French Health Products Safety Agency(Afssaps), will be heldJanuary 13th in Paris, France. Simon Robitaille, Chief Scientific Officer of TSO3, will be delivering the presentation on behalf of the Company.
"This meeting is part of a process aimed at helping France's Afssapsestablish a standard methodology for evaluating prion decontaminationtechnologies. Prions are abnormal proteins linked to VariantCreutzfeldt-Jakob disease (vCJD). The goal of the meeting is to allowleading experts, such as university-based scientists and hospital-basedhealth professionals, to exchange information on ways to compare theefficacy of different technologies to one common standard," saidMr. Robitaille. "This invitation demonstrates the level of recognition that ourscience is raising in the international health safety field. I lookforward to outlining our project to these experts who have shown suchan interest in our work," he added.
About TSO3
TSO3, founded in Québec City in 1998, specializes in the researchand development of innovative, high-performance medical instrumentsterilization technology with high commercial potential. The Company'sfirst product, the TSO3 STERIZONE(R) 125L Ozone Sterilizer, is designedfor sterile processing centers in the hospital environment.
In contrast to other methods used, the ozone sterilization processdeveloped and patented by TSO3 meets all standards required by theevolution in sterilization needs, which are: significant costs savings,increased safety for patients and hospital staff, and a "green"environmentally safe process.
The Company believes that its technology represents an advantageousreplacement solution to other low temperature sterilization processescurrently used in hospitals.
TSO3 STERIZONE(R) 125L Ozone Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada. TSO3 is in commercialization phase for this first product since 2006.
For more information about TSO3, visit the Company's Web site at www.tso3.com
The statements in this release and oral statements made byrepresentatives of TSO3 relating to matters that are not historicalfacts (including, without limitation, those regarding the timing oroutcome of any financing undertaken by TSO3 are forward-lookingstatements that involve certain risks, uncertainties and hypotheses,including, but not limited to, general business and economicconditions, the condition of the financial markets, the ability of TSO3to obtain financing on favourable terms and other risks anduncertainties.
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.
For further information: Marc Boisjoli, Vice President Finance andChief Financial Officer, (418) 651-0003, ext. 228, mboisjoli@tso3.com;Frédéric Tremblay, HKDP, (514) 395-0375, ext. 234, ir@tso3.com; Source:TSO3 Inc.
© CNW Group